Three years on from listing reforms, Hong Kong’s biotech investment ecosystem is booming

  • HKEX’s listing reforms launched in 2018 opened a new pathway for pre-revenue biotech companies to raise funds, fuelling an era of growth
  • Hong Kong has become Asia’s largest biotech fundraising hub, and the second-largest globally

READ FULL ARTICLE